Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC
Not yet recruiting · NCT07561983 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC | Chemoembolization, Therapeutic; Chemotherapy; Conversion Therapy; Tislelizumab; Unresectable Stage III Non-small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-05-01 | NCT07561983 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan Cancer Hospital and Research Institute | 64 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sichuan Cancer Hospital and Research Institute | Chengdu | China | 7 |